Gilead stops last PhI­II of CD47 drug, cit­ing FDA hold, high­er risk of death in treat­ment arm

Gilead dis­con­tin­ued its re­main­ing Phase III study of ma­grolimab, an an­ti-CD47 an­ti­body that the com­pa­ny was test­ing for acute myeloid leukemia and its pre­cur­sor dis­ease …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER